Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, P.R. China.
Aging (Albany NY). 2024 Apr 18;16(8):7131-7140. doi: 10.18632/aging.205747.
This study aims to evaluate the efficacy of various treatment approaches in stage T4b esophageal cancer patients.
Data were extracted from the Surveillance, Epidemiology, and End Results databases, covering patients diagnosed with esophageal cancer between 2000 and 2020. Kaplan-Meier analysis was used to assess cancer-specific survival (CSS) and overall survival (OS) across different treatment patterns.
The study included 482 patients: 222 (46.1%) received chemoradiotherapy, 58 (12.0%) underwent radiotherapy alone, 37 (7.7%) received chemotherapy alone, 50 (10.4%) underwent surgery, and 115 (23.8%) received no treatment. Median CSS were 12, 4, 6, 18, and 1 month for chemoradiotherapy, radiotherapy alone, chemotherapy alone, surgery, and non-treatment groups. Median OS for these groups were 11, 3, 6, 17, and 1 month, respectively. Multivariable proportional hazard regression analysis revealed that patients who underwent surgery experienced significantly improved CSS (hazard ratio [HR] = 0.42, 95% confidence interval [CI]: 0.24-0.72; P = 0.002) and OS (HR = 0.45, 95% CI: 0.28-0.74; P = 0.002) compared to those receiving chemoradiotherapy after propensity score matching.
Esophagectomy, with or without radiotherapy and/or chemotherapy, results in better survival outcomes than chemoradiotherapy in patients with stage T4b esophageal cancer.
本研究旨在评估 T4b 期食管癌患者的各种治疗方法的疗效。
数据来自 Surveillance, Epidemiology, and End Results 数据库，涵盖了 2000 年至 2020 年间诊断为食管癌的患者。采用 Kaplan-Meier 分析评估不同治疗模式下的癌症特异性生存（CSS）和总生存（OS）。
该研究纳入了 482 例患者：222 例（46.1%）接受放化疗，58 例（12.0%）单独接受放疗，37 例（7.7%）单独接受化疗，50 例（10.4%）接受手术，115 例（23.8%）未接受治疗。放化疗、单纯放疗、单纯化疗、手术和未治疗组的中位 CSS 分别为 12、4、6、18 和 1 个月。这些组的中位 OS 分别为 11、3、6、17 和 1 个月。多变量比例风险回归分析显示，与接受放化疗的患者相比，接受手术的患者 CSS（风险比 [HR] = 0.42，95%置信区间 [CI]：0.24-0.72；P = 0.002）和 OS（HR = 0.45，95% CI：0.28-0.74；P = 0.002）显著改善。在倾向评分匹配后。
对于 T4b 期食管癌患者，与放化疗相比，手术（联合或不联合放疗和/或化疗）可带来更好的生存结果。
